scholarly journals Effects of adjuvant chemotherapy on recurrence rate in T1abN0M0 triple-negative breast cancer: A meta-analysis

2020 ◽  
Vol 25 ◽  
pp. 100211
Author(s):  
Zijian Yang ◽  
Yonghua Chen ◽  
Xiaoling Liu ◽  
Junwei Cui ◽  
Yibing Hu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Recurrence Rate ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Meta Analysis

Absolute benefit from adjuvant chemotherapy in triple negative breast cancer (TNBC): A systemic review and meta-analysis.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e12501-e12501 ◽  
Author(s):  
Hadar Goldvaser ◽  
Domen Ribnikar ◽  
Habeeb Majeed ◽  
Alberto Ocana ◽  
Eitan Amir
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Meta Analysis ◽  
Systemic Review ◽  
Absolute Benefit

Tumor-infiltrating lymphocytes to predict survival to anthracycline/taxane-based adjuvant chemotherapy in triple negative breast cancer.

2018 ◽  
Vol 36 (5_suppl) ◽  
pp. 1-1
Author(s):  
Qiyun Ou ◽  
Yunfang Yu ◽  
Xiaoyun Xiao ◽  
Baoming Luo
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Breast Cancer Subtypes ◽  
Her2 Positive ◽  
Cancer Subtypes ◽  
Infiltrating Lymphocytes

1 Background: Previous clinical data suggested that the tumour-infiltrating lymphocytes (TILs) were predictive in breast cancer treated with adjuvant chemotherapy; however, clinical relevance has yet to be established. We hypothesized that TILs would be associated with overall survival (OS) and disease-free survival (DFS) after anthracycline/taxane-based adjuvant chemotherapy in breast cancer subtypes. Methods: PubMed and EMBASE were searched until March 2017 for studies that investigated the association of TILs with survival for anthracycline/taxane-based adjuvant chemotherapy in breast cancer. OS and DFS were combined using random-effects meta-analysis and calculated as combined hazard ratio (HR) with 95% credible intervals (CIs). The PROSPERO registry number is CRD42017072133. Results: Twelve studies comprising 9,023 patients were eligible for analysis. Six were prospective adjuvant trials (n = 7686) and six were retrospective studies (n = 1337). Pooled analysis indicated that high TILs have no significant predictive association in overall population (DFS, HR = 0.87, 95% CI, 0.70 – 1.08; OS, HR = 0.98, 95% CI, 0.89 – 1.07), Luminal A/B (DFS, HR = 0.99, 95% CI, 0.94 – 1.04; OS, HR = 1.01, 95% CI, 0.92 – 1.12), and HER2–positive patients (DFS, HR = 0.84, 95% CI, 0.71 – 1.00; OS, HR = 0.89, 95% CI, 0.77 – 1.02), but were related to improved DFS (HR, 0.81; 95% CI, 0.73 – 0.89) and OS (HR, 0.74; 95% CI, 0.66 – 0.84) in triple negative breast cancer (TNBC) patients. Additionally, increasing TILs were not significantly associated with reduced risk of relapse in HER2-positive patient through adjuvant trastuzumab (HR, 0.97; 95% CI, 0.93 – 1.01). Conclusions: This meta-analysis provides an evidence that TILs predicts survival to anthracycline/taxane-based adjuvant chemotherapy in TNBC patients and suggests that predictive benefit seemed to be influenced by breast cancer subtypes as well.

scholarly journals The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Xingfa Huo ◽  
Jinming Li ◽  
Fuxing Zhao ◽  
Dengfeng Ren ◽  
Raees Ahmad ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Randomized Clinical Trials ◽  
Triple Negative ◽  
Early Stage ◽  
Meta Analysis ◽  
Disease Free Survival

Abstract Background The role of capecitabine in neoadjuvant and adjuvant chemotherapy for early-stage triple-negative breast cancer (TNBC) is highly controversial. Our meta-analysis was designed to further elucidate the effects of capecitabine on survival in early-stage TNBC patients and its safety. Methods PubMed, Embase, and papers presented at several main conferences were searched up to December 19, 2019, to investigate capecitabine-based versus capecitabine-free neoadjuvant and adjuvant chemotherapy in TNBC patients. Heterogeneity was assessed using I2 test, combined with hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CI) computed for disease-free survival (DFS), overall survival (OS), and over grade 3 adverse events (AEs). Results A total of 9 randomized clinical trials and 3842 TNBC patients were included. Overall, the combined capecitabine regimens in neoadjuvant and adjuvant chemotherapy showed significantly improved DFS (HR = 0.75; 95% CI, 0.65–0.86; P < 0.001) and OS (HR = 0.63; 95% CI, 0.53–0.77; P < 0.001). In subgroup analysis, there were improvements in DFS in the groups with addition of capecitabine (HR = 0.64; 95% CI, 0.53–0.78; P < 0.001), adjuvant chemotherapy (HR = 0.73; 95% CI, 0.63–0.85; P < 0.001), and lymph node positivity (HR = 0.62; 95% CI, 0.44–0.86; P = 0.005). Capecitabine regimens were related to higher risks of diarrhea (OR = 2.88, 95% CI 2.23–3.74, P < 0.001), stomatitis (OR = 2.01, 95% CI 1.53–2.64, P < 0.001) and hand–foot syndrome (OR = 8.67, 95% CI 6.70–11.22, P < 0.001). Conclusion This meta-analysis showed that neoadjuvant and adjuvant chemotherapy combined with capecitabine significantly improved both DFS and OS in early-stage TNBC patients with tolerable AEs. There were benefits to DFS in the groups with the addition of capecitabine, adjuvant chemotherapy, and lymph node positivity.

scholarly journals Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis of 36480 cases. 

2020 ◽  
Author(s):  
Lin-Yu Xia ◽  
Qing-Lin Hu ◽  
Jing Zhang ◽  
Wei-Yun Xu ◽  
Xiao-Shi Li
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Residual Disease ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Current Evidence ◽  
Survival Outcomes ◽  
Significant Difference

Abstract Background: The survival outcomes of neoadjuvant chemotherapy (NACT) versus adjuvant chemotherapy (ACT) for patients with triple-negative breast cancer (TNBC) remain unclear. Therefore, in this study, a meta-analysis was conducted to analyze current evidence on the survival outcomes of NACT versus ACT in TNBC. Methods: A systematic search was performed on the PubMed and Embase databases to identify relevant articles investigating the survival outcomes of NACT versus ACT in TNBC. Results: A total of nine studies involving 36480 patients met the selection criteria. Among them,10728 (29.41%) received NACT, and 25752 (70.59%) received ACT. The pathological complete response (pCR) rate was 35% (95% CI = 0.23-0.48). Compared with ACT, the overall survival (OS) of NACT was poor (HR = 1.59; 95%CI = 1.25-2.02; P=0.0001), and there was no significant difference in disease-free survival (DFS) between the two treatments (HR = 0.85; 95%CI = 0.54-1.34; P=0.49). NACT with pCR significantly improved the OS (HR = 0.53; 95%CI = 0.29-0.98; P=0.04) and DFS (HR = 0.52; 95%CI = 0.29-0.94; P=0.03), while the OS (HR = 1.18; 95%CI = 1.09-1.28; P<0.0001) and DFS (HR = 2.36; 95%CI = 1.42-3.89; P=0.0008) of patients with residual disease (RD) following NACT were worse compared to those receiving ACT. Conclusion: These findings suggest that, for TNBC, NACT with pCR is superior to ACT in improving OS and DFS. and it turns to be opposite when patients receiving NACT with RD.

scholarly journals Survival outcomes of neoadjuvant versus adjuvant chemotherapy in triple-negative breast cancer: a meta-analysis in 36480 cases.

2020 ◽  
Author(s):  
Lin-Yu Xia ◽  
Qing-Lin Hu ◽  
Jing Zhang ◽  
Wei-Yun Xu ◽  
Xiao-Shi Li
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Residual Disease ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
Current Evidence ◽  
Survival Outcomes ◽  
Significant Difference

Abstract Background The survival outcomes of neoadjuvant chemotherapy(NACT) versus adjuvant chemotherapy(ACT) in triple-negative breast cancer (TNBC) remains unclear. Therefore, in this study, a meta-analysis was conducted to analyze current evidence on the survival outcomes of neoadjuvant versus ACT in TNBC. Methods A systematic search of PubMed and Embase databases were done to identify relevant articles investigating the survival outcomes of NACT versus ACT in TNBC. Results A total of nine studies involving 36480 patients met the selection criteria.Of them,10728(29.41%) received NACT, and 25752(70.59%) received ACT.The pathological complete response (pCR) rate is 35% (95% CI = 0.23-0.48). Compared with ACT, the overall survival(OS) of NACT was poor(HR = 1.59; 95%CI = 1.25-2.02; P=0.0001), and there was no significant difference in disease-free survival(DFS) between them(HR = 0.85; 95%CI = 0.54-1.34; P=0.49). NACT with pCR can significantly improve the OS(HR = 0.53; 95%CI = 0.29-0.98; P=0.04) and DFS(HR = 0.52; 95%CI = 0.29-0.94; P=0.03), while the OS(HR = 1.18; 95%CI = 1.09-1.28; P<0.0001) and DFS(HR = 2.36; 95%CI = 1.42-3.89; P=0.0008) of patients with residual disease(RD) following NACT were worse compared with ACT. Conclusion The findings suggest that, for TNBC, Patients receiving NACT with pCR can significantly improve OS and DFS compared with ACT and it turns to be opposite when patients receiving NACT with RD.

Adjuvant chemotherapy for pT1abN0M0 triple-negative breast cancer: a systematic review and meta-analysis of published studies

2021 ◽  
Vol 147 ◽  
pp. 151-153
Author(s):  
Fausto Petrelli ◽  
Maria Chiara Parati ◽  
Karen Borgonovo ◽  
Mary Cabiddu ◽  
Mara Ghilardi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Meta Analysis

scholarly journals Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis

Genes ◽  
2021 ◽  
Vol 12 (4) ◽  
pp. 549
Author(s):  
Amal Qattan ◽  
Taher Al-Tweigeri ◽  
Wafa Alkhayal ◽  
Kausar Suleman ◽  
Asma Tulbah ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Drug Resistance ◽  
Triple Negative Breast Cancer ◽  
Drug Response ◽  
Triple Negative ◽  
Meta Analysis ◽  
Integrated Analysis ◽  
Circulating Mirnas ◽  
Persistent Problem ◽  
Network Analyses

Resistance to therapy is a persistent problem that leads to mortality in breast cancer, particularly triple-negative breast cancer (TNBC). MiRNAs have become a focus of investigation as tissue-specific regulators of gene networks related to drug resistance. Circulating miRNAs are readily accessible non-invasive potential biomarkers for TNBC diagnosis, prognosis, and drug-response. Our aim was to use systems biology, meta-analysis, and network approaches to delineate the drug resistance pathways and clinical outcomes associated with circulating miRNAs in TNBC patients. MiRNA expression analysis was used to investigate differentially regulated circulating miRNAs in TNBC patients, and integrated pathway regulation, gene ontology, and pharmacogenomic network analyses were used to identify target genes, miRNAs, and drug interaction networks. Herein, we identified significant differentially expressed circulating miRNAs in TNBC patients (miR-19a/b-3p, miR-25-3p, miR-22-3p, miR-210-3p, miR-93-5p, and miR-199a-3p) that regulate several molecular pathways (PAM (PI3K/Akt/mTOR), HIF-1, TNF, FoxO, Wnt, and JAK/STAT, PD-1/PD-L1 pathways and EGFR tyrosine kinase inhibitor resistance (TKIs)) involved in drug resistance. Through meta-analysis, we demonstrated an association of upregulated miR-93, miR-210, miR-19a, and miR-19b with poor overall survival outcomes in TNBC patients. These results identify miRNA-regulated mechanisms of drug resistance and potential targets for combination with chemotherapy to overcome drug resistance in TNBC. We demonstrate that integrated analysis of multi-dimensional data can unravel mechanisms of drug-resistance related to circulating miRNAs, particularly in TNBC. These circulating miRNAs may be useful as markers of drug response and resistance in the guidance of personalized medicine for TNBC.

Sign in / Sign up

Export Citation Format

Share Document